THU0119

SUCCESSFUL PSYCHOPHARMACOTHERAPY OF ANXIETY AND DEPRESSIVE DISORDERS IMPROVES RHEUMATOID ARTHRITIS REMISSION RATE AT FIVE YEARS FOLLOW-UP

Anton Abramkin¹, Tatiana Lisitsyna¹, Dmitry Veltishchev², Olga Seravina², Oksana Kovalevskaya², Svetlana Glukhova¹, Evgeny Nasonov¹. ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; ²Moscow Research Institute of Psychiatry, «National Medical Research Center of Psychiatry and Narcology» Ministry of Health of Russia, Stress disorders, Moscow, Russian Federation

Background: Anxiety and depressive disorders (ADD) affect rheumatoid arthritis (RA) disease activity and remission rate. Psychopharmacotherapy (PPT) of ADD attempts to improve the remission rate.

Objectives: To determine factors associated with RA remission rate.

Methods: 128 RA-patients (pts) were enrolled, 86% were women with a mean age of 47.4±11.3 (M±SD) yrs. All pts met the full ACR criteria for RA. Remission was defined as DAS28<2.6. Mean RA activity by DAS28 was high (5.27±1.78) at baseline. 69.4% RA-pts were already taking prednisone (9 [5; 10] mg/day (Me (25%; 75%)), 84.4% - conventional disease-modifying antirheumatic drugs (cDMARDs), 7.8% - biologic DMARDs (bDMARDs) - anti-TNF- α - 6.3%, rituximab - 1.6%. ADD were diagnosed in 123 (96.1%) of RA-pts in accordance with ICD-10 in semi-structured interview. Severity of depression and anxiety was evaluated with Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A). RA-pts with ADD were divided into the following treatment groups: 1 - cDMARDs (n=39), 2 - cDMARDs + PPT (sertraline or mianserine) (n=43), 3 - cDMARDs + bDMARDs (n=32), 4 - cDMARDs + bDMARDs + PPT (sertraline or mianserine) (n=9). Biologics treatment duration varied from 1 to 6 years, antidepressants - from 6 to 96 weeks. Logistic regression analysis was conducted to determine factors associated with RA remission rate.

Results: At 5-yrs endpoint in 83 RA-pts remission rate was 22.9% (8.3%, 34.5%, 19.0% and 33.3% in groups 1, 2, 3 and 4, respectively). Significantly higher proportion of patients achieved remission in cDMARDs + PPT group vs cDMARDs group (34.5% vs 8.3%, RR 1.8 (95%CI 0.35 - 9.2), p=0.024). By univariate logistic regression, male sex, younger age, shorter RA duration, RF and ACPA negativity, lower baseline DAS28 and HAQ, absence of extraarticular RA manifestations and depression at the beginning of the study, and remission of anxiety and depressive symptoms at the end of the study were significantly associated with RA remission (table 1). These variables were subjected to multivariate stepwise logistic regression. Only lower baseline DAS28 (OR 0.636 (95%CI 0.515 - 0.785), p<0.001) and remission of anxiety and depressive symptoms at 5-yrs endpoint (OR 6.89 (95%CI 1.8 - 26.29), p=0.005) were independently associated with RA remission at 5-years follow-up.

Table 1. Factors associated with RA remission at 5 years (univariate logistic regression).

Factor	p	OR	95%CI	
			low	up
Female sex	<0.001	0.310	0.166	0.577
Baseline age	<0.001	0.974	0.961	0.986
RA duration	0.001	0.913	0.866	0.964
RF +	<0.001	0.265	0.127	0.552
ACPA +	0.003	0.321	0.152	0.681
Baseline DAS28	<0.001	0.754	0.663	0.858
Baseline HAQ	<0.001	0.381	0.236	0.614
Baseline extraarticular RA manifestations	0.005	0.211	0.072	0.619
Baseline minor depression	0.011	0.278	0.103	0.748
Baseline major depression	0.028	0.353	0.139	0.895
Baseline generalized anxiety disorder	0.215	0.25	0.028	2.237
Anxiety and depressive symptoms remission at 5-yrs endpoint	0.007	5.891	1.63	21.29
Schizotypal personality disorder	0.22	0.429	0.111	1.657

Conclusion: Lower baseline DAS28 and remission of anxiety and depressive symptoms at 5-yrs endpoint are associated with higher rheumatoid arthritis remission rate at five years follow-up.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.3553

THU0120

RHEUMATIC DISEASE COMORBIDITY INDEX IMPACT ON DISEASE ACTIVITY IN PATIENTS ENROLLED IN KUWAIT REGISTRY OF RHEUMATIC DISEASES (KRRD)

YASER Ali^{1,1}, Khulood Saleh², Ahmed Enizi³, Fatemah Abutiban³, Adel Al-Awadhi⁴, Waleed Al-Kandari², Eman Hasan⁴, Hebah Alhajeri¹, Mohammed Hussain⁴, Ahmed Alsaber², Sawzan Hayat¹, Ali Aledeh⁴, Adeeba Herz⁴, Aqeel Ghanem¹. ¹Mubarak Al Kabeer Hospital, Rheumatology, Kuwait city, Kuwait; ²Farwania Hospital, Kuwait city, Kuwait; ³Al Jahrs Hospital, Kuwait city, Kuwait; ⁴Amiri Hospital, Kuwait city, Kuwait; ⁵Kuwait Technical college, Department of Mathematics, Kuwait city, Kuwait

Background: Its known that the presence of certain comorbidities in patients with Rheumatoid arthritis (RA) can have an impact on the chance of achieving low disease activity (LDA).

Objectives: The purpose of this study was to examine the association of different comorbidities with low disease activity index in patients enrolled in KRRD.

Methods: The database of KRRD was used to include patients with RA and multiple visits. Comorbid conditions were collected at enrollment by the treating rheumatologist and modeled using the Rheumatic Disease Comorbidity index (RDCI) score, and by individual comorbid condition. Disease activity (DAS28) was assessed at routine clinic visits. Associations of comorbidity measures with disease activity over 4 years of follow up were examined using multivariable linear models. The odds of ever achieving DAS28 low disease activity (<3.2) were examined using multivariable logistic regression.

Results: Among 1511 participants with mean age of 52 (SD 12) years, RA duration 8 (SD 6) years, 60.7% female, 77.1% RF positive, 64.6% anti-CCP positive, and 10.8% with smoking history, 1.29 had a RDCI. Hypertension (21%), diabetes mellitus (21%), hyperlipidemia (12%), cardiovascular (CV) disease (3.6%) and interstitial lung disease (ILD) (1.1%), were the most prevalent comorbidities. Select individual comorbidities, including DM, kidney disease and COPD, were more closely associated with unfavorable longitudinal disease activity, and achievement of low disease activity status. Correlation test between DAS28 and all comorbidities showed significant negative association for achieving low disease activity if the patient has history of diabetes mellitus, COPD or kidney disease.

Conclusion: DM, kidney disease and COPD but not composite comorbidity scores, are associated with higher measures of disease activity and lower odds of achieving low disease activity status in RA patients enrolled in KRRD registry.

Table (1) : Cox Proportional Hazards Regression for LDA and comorbidities

Variable	B	SE	95% CI	P	OR
DM	0.24	0.05	(0.14, 0.34)	0.001	1.27
CAD	0.16	0.13	(-0.09, 0.40)	0.221	1.17
Hyperlipidemia	-0.12	0.06	(-0.24, 0.01)	0.65	0.89
Hypertension	-0.04	0.05	(-0.14, 0.05)	0.394	0.96
COPD	0.66	0.33	(0.01, 1.32)	0.047	1.94
Cancer	0.86	0.45	(-0.02, 1.74)	0.055	2.36
Kidney disease	0.97	0.39	(0.20, 1.74)	0.014	2.63
ILD	0.09	0.21	(-0.33, 0.50)	0.685	1.09

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.445

THU0121

CIRCULATING FIBROBLAST GROWTH FACTOR-23 IS ASSOCIATED WITH DYSLIPIDEMIA IN RHEUMATOID ARTHRITIS PATIENTS

Antonio Alvarez de Cienfuegos¹, Lucia Cantero-Nieto², José Alberto García-Gómez³, Gema Robledo⁴, Marta Trigo⁵, Javier Martín Ibanez⁶, Miguel A González-Gay⁶, Norberto Ortego⁷. ¹Vega Baja Hospital, Rheumatology, Orihuela, Spain; ²Santa Ana Hospital, Emergency, Granada, Spain; ³Hospital General Universitario d'Elx, Elche, Spain; ⁴Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain; ⁵Hospital San Cecilio, Internal Medicine, Granada, Spain; ⁶IDIVAL, Santander, Spain; ⁷Hospital Universitario San Cecilio, Internal Medicine, Granada, Spain

Background: Rheumatoid arthritis (RA) patients have an increased risk of morbidity and mortality from cardiovascular (CV) events as a result of accelerated atherosclerosis. The bone-derived fibroblast growth factor-23 (FGF23) is a novel marker of chronic kidney disease (CKD)-associated mineral bone disorder, which increases progressively with declining renal function. FGF23 is associated with left ventricular hypertrophy, impaired left ventricular function, endothelial dysfunction, heart failure and progression of renal failure in adult CKD.